



CASE 100-7317M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1614

Schuler et al.

EXAMINER: Gembah, Shirley V.

APPLICATION NO.: 10/092,639

DATE: February 7, 2008

FILED: March 7, 2002

FOR: USE OF RAPAMYCIN DERIVATIVES IN VASCULOPATHIES AND
XENOTRANSPLANTATION

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER

Sir:


Enclosed herewith is a Terminal Disclaimer in the above-identified application.

Also enclosed is a check in the amount of \$130.00 to cover the fee under 37 CFR
§1.20(d).

The Commissioner is hereby authorized to charge any additional fees that may be
required to Deposit Account No. 04-1121 in the name of Dilworth and Barrese. An additional
copy of this paper is here enclosed.

Respectfully submitted,


Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080


Ann R. Pokalsky
Attorney for Applicants
Reg. No. 34,697

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to the: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450 on February 7, 2008.

Dated: February 7, 2008


Ann R. Pokalsky